siRNA therapy can reduce important risk factors of cardiovascular disease by 98%. Phase 1 clinical results of siRNA therapy are positive

Silence Therapeutics announced today that its investigational small interfering RNA (siRNA) therapy SLN360 has achieved positive results in a single-dose escalation Phase 1 clinical trial

High Lp(a), defined as plasma Lp(a) levels ≥50 mg/dL, affects approximately 20% of the world's population and is a genetic risk factor for cardiovascular disease

This study evaluated the safety, tolerability, and pharmacokinetics of escalating doses of SLN360 in 32 adults with plasma Lp(a) ≥150 nmol/L (approximately ≥60 mg/dL) and no known cardiovascular disease (PK) and pharmacodynamic characteristics

The primary safety end point was to assess adverse events that occurred after treatment

The key efficacy measure was the percent change from baseline in Lp(a)

References:

[1] Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a).

(Original abridged)